Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Accounts Payables: 2016-2025

Historic Accounts Payables for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $13.6 million.

  • Rhythm Pharmaceuticals' Accounts Payables rose 178.92% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 178.92%. This contributed to the annual value of $12.3 million for FY2024, which is 152.36% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Accounts Payables stood at $13.6 million for Q3 2025, which was down 14.71% from $16.0 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Accounts Payables ranged from a high of $16.0 million in Q2 2025 and a low of $3.8 million during Q3 2023.
  • In the last 3 years, Rhythm Pharmaceuticals' Accounts Payables had a median value of $8.4 million in 2023 and averaged $9.2 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Accounts Payables plummeted by 45.81% in 2024, and later skyrocketed by 251.79% in 2025.
  • Rhythm Pharmaceuticals' Accounts Payables (Quarterly) stood at $5.7 million in 2021, then decreased by 16.38% to $4.8 million in 2022, then rose by 1.83% to $4.9 million in 2023, then skyrocketed by 152.36% to $12.3 million in 2024, then soared by 178.92% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q3 2025, $16.0 million for Q2 2025, and $11.9 million during Q1 2025.